Press Releases | Clarus Therapeutics, Inc

Skip to main navigation

Investor Overview
News & Events
- Press Releases
- Events and Presentations
Stock Information
Corporate Governance
Financials & Filings
- SEC Filings
- Quarterly & Annual Reports
IR Resources
- Email Alerts
- Contact IR

Press Releases

Year

Apr 28, 2022

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)

Apr 27, 2022

Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering

Apr 25, 2022

Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering

Apr 19, 2022

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual Meeting

Mar 30, 2022

Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

Mar 29, 2022

Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results

Mar 16, 2022

Clarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadal Men with Chronic Kidney Disease

Mar 10, 2022

Clarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

Feb 24, 2022

Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to Patients

Jan 18, 2022

Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 20 of 20

2022 Copyright

Search Investor Relations